Delshad Sean D, Kleiber Angela
Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, USA.
Cureus. 2023 May 15;15(5):e39063. doi: 10.7759/cureus.39063. eCollection 2023 May.
Colchicine has a narrow therapeutic window and a high risk of toxicity when co-administered with CYP3A4 inhibitors and P-glycoprotein inhibitors. Colchicine toxicity is associated with various metabolic disturbances and can cause multiorgan failure and death. However, to our knowledge, there are no documented reports of colchicine toxicity initially presenting as euglycemic diabetic ketoacidosis (DKA). We present a case of colchicine toxicity with concomitant euglycemic DKA in a man with long-term colchicine use who was also prescribed clarithromycin and dapagliflozin.
秋水仙碱的治疗窗较窄，与CYP3A4抑制剂和P-糖蛋白抑制剂合用时毒性风险较高。秋水仙碱毒性与多种代谢紊乱有关，可导致多器官功能衰竭和死亡。然而，据我们所知，尚无文献报道秋水仙碱毒性最初表现为血糖正常的糖尿病酮症酸中毒（DKA）。我们报告一例长期使用秋水仙碱且同时服用克拉霉素和达格列净的男性患者发生秋水仙碱毒性并伴有血糖正常的DKA的病例。
